{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:26:23Z","timestamp":1788452783189,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI071002"],"award-info":[{"award-number":["AI071002"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI171403"],"award-info":[{"award-number":["AI171403"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Microbiol"],"DOI":"10.1038\/s41564-026-02419-y","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T09:02:25Z","timestamp":1784883745000},"page":"2505-2514","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antiviral GHP-88310 blocks contact-mediated and airborne transmission in a ferret model of measles-like disease"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6845-2746","authenticated-orcid":false,"given":"Carolin M.","family":"Lieber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2507-6944","authenticated-orcid":false,"given":"Josef D.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7223-7857","authenticated-orcid":false,"given":"Claire E.","family":"Ruckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren A.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2034-2107","authenticated-orcid":false,"given":"Richard K.","family":"Plemper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"2419_CR1","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3390\/vaccines12060693","volume":"12","author":"P Strebel","year":"2024","unstructured":"Strebel, P., Grabowsky, M., Hoekstra, E., Gay, A. & Cochi, S. Evolution and contribution of a global partnership against measles and rubella, 2001\u20132023. Vaccines 12, 693 (2024).","journal-title":"Vaccines"},{"key":"2419_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.49","volume":"2","author":"PA Rota","year":"2016","unstructured":"Rota, P. A. et al. Measles. Nat. Rev. Dis. Primers 2, 16049 (2016).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"2419_CR3","doi-asserted-by":"crossref","unstructured":"Progress Toward Measles Elimination\u2014Worldwide, 2000\u20132023 (CDC, 2024); https:\/\/www.cdc.gov\/mmwr\/volumes\/73\/wr\/mm7345a4.htm","DOI":"10.15585\/mmwr.mm7345a4"},{"key":"2419_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.coviro.2020.02.007","volume":"41","author":"RK Plemper","year":"2020","unstructured":"Plemper, R. K. Measles resurgence and drug development. Curr. Opin. Virol. 41, 8\u201317 (2020).","journal-title":"Curr. Opin. Virol."},{"key":"2419_CR5","unstructured":"Health Protection Report. Confirmed measles cases in England and Wales - an update to the end of October 2008. The National Archives https:\/\/webarchive.nationalarchives.gov.uk\/ukgwa\/20140714101910\/http:\/\/www.hpa.org.uk\/hpr\/archives\/2008\/news4808.htm#measles (2008)."},{"key":"2419_CR6","unstructured":"European Region Reports Highest Number of Measles Cases in More Than 25 Years (WHO, 2025); https:\/\/www.who.int\/europe\/news\/item\/13-03-2025-european-region-reports-highest-number-of-measles-cases-in-more-than-25-years\u2013unicef\u2013who-europe"},{"key":"2419_CR7","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0140-6736(08)61849-8","volume":"373","author":"M Muscat","year":"2009","unstructured":"Muscat, M., Bang, H., Wohlfahrt, J., Glismann, S. & Molbak, K. Measles in Europe: an epidemiological assessment. Lancet 373, 383\u2013389 (2009).","journal-title":"Lancet"},{"key":"2419_CR8","unstructured":"Measles Cases and Outbreaks (CDC, 2025); https:\/\/www.cdc.gov\/measles\/data-research\/index.html"},{"key":"2419_CR9","unstructured":"Measles in the Region of the Americas (World Health Organization, 2025); https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2025-DON565"},{"key":"2419_CR10","unstructured":"Measles and Rubella Weekly Monitoring Report (Government of Canada, 2025)."},{"key":"2419_CR11","doi-asserted-by":"publisher","first-page":"926","DOI":"10.3390\/vaccines11050926","volume":"11","author":"MLB Novilla","year":"2023","unstructured":"Novilla, M. L. B. et al. Why parents say no to having their children vaccinated against measles: a systematic review of the social determinants of parental perceptions on MMR vaccine hesitancy. Vaccines 11, 926 (2023).","journal-title":"Vaccines"},{"key":"2419_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2024.102648","volume":"18","author":"C Cagnotta","year":"2025","unstructured":"Cagnotta, C. et al. Parental vaccine hesitancy: recent evidences support the need to implement targeted communication strategies. J. Infect. Public Health 18, 102648 (2025).","journal-title":"J. Infect. Public Health"},{"key":"2419_CR13","first-page":"e88196","volume":"17","author":"AF Adeoye","year":"2025","unstructured":"Adeoye, A. F. et al. The 2025 United States measles crisis: when vaccine hesitancy meets reality. Cureus 17, e88196 (2025).","journal-title":"Cureus"},{"key":"2419_CR14","unstructured":"Beusekom, M. V. Two New Studies Predict Results of Declining MMR Uptake, Restricting Non-medical Vaccine Exemptions (Center for Infectious Disease Research and Policy (CIDRAP), 2025); https:\/\/www.cidrap.umn.edu\/childhood-vaccines\/two-new-studies-predict-results-declining-mmr-uptake-restricting-non-medical"},{"key":"2419_CR15","unstructured":"Savchuk, K. Measles May Be Making a Comeback in the U.S. (Stanford Medicine News Center, 2025); https:\/\/med.stanford.edu\/news\/all-news\/2025\/04\/measles-vaccination.html"},{"key":"2419_CR16","unstructured":"Rosen, J. New Data Shows MMR Vaccination Rate Decline Across the U.S. Johns Hopkins University HUB (2025); https:\/\/hub.jhu.edu\/2025\/06\/03\/united-states-measles-vaccination-rate-declines\/"},{"key":"2419_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-7-52","volume":"7","author":"Y Furuse","year":"2010","unstructured":"Furuse, Y., Suzuki, A. & Oshitani, H. Origin of measles virus: divergence from rinderpest virus between the 11th and 12th centuries. Virol. J. 7, 52 (2010).","journal-title":"Virol. J."},{"key":"2419_CR18","doi-asserted-by":"publisher","first-page":"e1002058","DOI":"10.1371\/journal.ppat.1002058","volume":"7","author":"RK Plemper","year":"2011","unstructured":"Plemper, R. K., Brindley, M. A. & Iorio, R. M. Structural and mechanistic studies of measles virus illuminate paramyxovirus entry. PLoS Pathog. 7, e1002058 (2011).","journal-title":"PLoS Pathog."},{"key":"2419_CR19","unstructured":"Plemper, R. K. & Lamb, R. A. In Fields Virology Vol. 1 (eds Knipe, D. M. et al.) Ch. 33, 504\u2013558 (Wolters Kluwer\/Lippincott Williams & Wilkins, 2020)."},{"key":"2419_CR20","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1016\/S0140-6736(17)31463-0","volume":"390","author":"WJ Moss","year":"2017","unstructured":"Moss, W. J. Measles. Lancet 390, 2490\u20132502 (2017).","journal-title":"Lancet"},{"key":"2419_CR21","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3390\/microorganisms8020276","volume":"8","author":"A Misin","year":"2020","unstructured":"Misin, A. et al. Measles: an overview of a re-emerging disease in children and immunocompromised patients. Microorganisms 8, 276 (2020).","journal-title":"Microorganisms"},{"key":"2419_CR22","unstructured":"Clinical Overview of Measles (CDC, 2025); https:\/\/www.cdc.gov\/measles\/hcp\/clinical-overview\/index.html"},{"key":"2419_CR23","doi-asserted-by":"publisher","first-page":"e1009371","DOI":"10.1371\/journal.ppat.1009371","volume":"17","author":"RM Cox","year":"2021","unstructured":"Cox, R. M., Sourimant, J., Govindarajan, M., Natchus, M. G. & Plemper, R. K. Therapeutic targeting of measles virus polymerase with ERDRP-0519 suppresses all RNA synthesis activity. PLoS Pathog. 17, e1009371 (2021).","journal-title":"PLoS Pathog."},{"key":"2419_CR24","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1038\/s41564-020-0752-7","volume":"5","author":"RM Cox","year":"2020","unstructured":"Cox, R. M. et al. Orally efficacious broad-spectrum allosteric inhibitor of paramyxovirus polymerase. Nat. Microbiol. 5, 1232\u20131246 (2020).","journal-title":"Nat. Microbiol."},{"key":"2419_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45418-5","volume":"15","author":"RM Cox","year":"2024","unstructured":"Cox, R. M. et al. Therapeutic mitigation of measles-like immune amnesia and exacerbated disease after prior respiratory virus infections in ferrets. Nat. Commun. 15, 1189 (2024).","journal-title":"Nat. Commun."},{"key":"2419_CR26","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00806-24","volume":"98","author":"GD Haas","year":"2024","unstructured":"Haas, G. D. et al. Tetracistronic minigenomes elucidate a functional promoter for Ghana virus and unveils Cedar virus replicase promiscuity for all henipaviruses. J. Virol. 98, e0080624 (2024).","journal-title":"J. Virol."},{"key":"2419_CR27","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01850-23","volume":"98","author":"KS Schmitz","year":"2024","unstructured":"Schmitz, K. S. et al. Rational attenuation of canine distemper virus (CDV) to develop a morbillivirus animal model that mimics measles in humans. J. Virol. 98, e0185023 (2024).","journal-title":"J. Virol."},{"key":"2419_CR28","doi-asserted-by":"publisher","first-page":"232ra252","DOI":"10.1126\/scitranslmed.3008517","volume":"6","author":"SA Krumm","year":"2014","unstructured":"Krumm, S. A. et al. An orally available, small-molecule polymerase inhibitor shows efficacy against a lethal morbillivirus infection in a large animal model. Sci. Transl. Med. 6, 232ra252 (2014).","journal-title":"Sci. Transl. Med."},{"key":"2419_CR29","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1182\/blood-2006-12-060343","volume":"110","author":"AJ Peck","year":"2007","unstructured":"Peck, A. J. et al. Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection. Blood 110, 1681\u20131688 (2007).","journal-title":"Blood"},{"key":"2419_CR30","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1182\/blood.V98.3.573","volume":"98","author":"WG Nichols","year":"2001","unstructured":"Nichols, W. G., Corey, L., Gooley, T., Davis, C. & Boeckh, M. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 98, 573\u2013578 (2001).","journal-title":"Blood"},{"key":"2419_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aef1594","volume":"12","author":"CM Lieber","year":"2026","unstructured":"Lieber, C. M. et al. Developmental candidate GHP-88310\/EIDD-3608 with high tolerability and oral efficacy in measles and respiratory paramyxovirus models. Sci. Adv. 12, eaef1594 (2026).","journal-title":"Sci. Adv."},{"key":"2419_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21918-6","volume":"12","author":"JS Kutter","year":"2021","unstructured":"Kutter, J. S. et al. SARS-CoV and SARS-CoV-2 are transmitted through the air between ferrets over more than one meter distance. Nat. Commun. 12, 1653 (2021).","journal-title":"Nat. Commun."},{"key":"2419_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17367-2","volume":"11","author":"M Richard","year":"2020","unstructured":"Richard, M. et al. SARS-CoV-2 is transmitted via contact and via the air between ferrets. Nat. Commun. 11, 3496 (2020).","journal-title":"Nat. Commun."},{"key":"2419_CR34","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41564-024-01885-6","volume":"10","author":"II Tosheva","year":"2025","unstructured":"Tosheva, I. I. et al. Influenza A(H5N1) shedding in air corresponds to transmissibility in mammals. Nat. Microbiol. 10, 14\u201319 (2025).","journal-title":"Nat. Microbiol."},{"key":"2419_CR35","doi-asserted-by":"publisher","first-page":"4074","DOI":"10.1016\/j.cell.2023.08.011","volume":"186","author":"H Sun","year":"2023","unstructured":"Sun, H. et al. Airborne transmission of human-isolated avian H3N8 influenza virus between ferrets. Cell 186, 4074\u20134084.e11 (2023).","journal-title":"Cell"},{"key":"2419_CR36","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3390\/pathogens11070732","volume":"11","author":"AH Haselbeck","year":"2022","unstructured":"Haselbeck, A. H. et al. Serology as a tool to assess infectious disease landscapes and guide public health policy. Pathogens 11, 732 (2022).","journal-title":"Pathogens"},{"key":"2419_CR37","doi-asserted-by":"publisher","first-page":"6418","DOI":"10.1128\/JVI.75.14.6418-6427.2001","volume":"75","author":"V von Messling","year":"2001","unstructured":"von Messling, V., Zimmer, G., Herrler, G., Haas, L. & Cattaneo, R. The hemagglutinin of canine distemper virus determines tropism and cytopathogenicity. J. Virol. 75, 6418\u20136427 (2001).","journal-title":"J. Virol."},{"key":"2419_CR38","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1128\/JVI.06414-11","volume":"86","author":"B Sawatsky","year":"2012","unstructured":"Sawatsky, B., Wong, X. X., Hinkelmann, S., Cattaneo, R. & von Messling, V. Canine distemper virus epithelial cell infection is required for clinical disease but not for immunosuppression. J. Virol. 86, 3658\u20133666 (2012).","journal-title":"J. Virol."},{"key":"2419_CR39","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.1128\/JVI.79.9.5857-5862.2005","volume":"79","author":"V von Messling","year":"2005","unstructured":"von Messling, V. et al. Nearby clusters of hemagglutinin residues sustain SLAM-dependent canine distemper virus entry in peripheral blood mononuclear cells. J. Virol. 79, 5857\u20135862 (2005).","journal-title":"J. Virol."},{"key":"2419_CR40","unstructured":"Measles (Lancaster County Department of Public Safety, 2025); https:\/\/www.co.lancaster.pa.us\/2983\/Measles"},{"key":"2419_CR41","unstructured":"How Measles Spreads (CDC, 2024); https:\/\/www.cdc.gov\/measles\/causes\/index.html"},{"key":"2419_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.126706","volume":"47","author":"J Montroy","year":"2025","unstructured":"Montroy, J. et al. Post-exposure prophylaxis for the prevention of measles: a systematic review. Vaccine 47, 126706 (2025).","journal-title":"Vaccine"},{"key":"2419_CR43","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1080\/21645515.2018.1474310","volume":"14","author":"PA Gasta\u00f1aduy","year":"2018","unstructured":"Gasta\u00f1aduy, P. A. et al. Public health responses during measles outbreaks in elimination settings: strategies and challenges. Hum. Vaccin. Immunother. 14, 2222\u20132238 (2018).","journal-title":"Hum. Vaccin. Immunother."},{"key":"2419_CR44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coviro.2020.08.002","volume":"46","author":"DE Griffin","year":"2021","unstructured":"Griffin, D. E. Measles immunity and immunosuppression. Curr. Opin. Virol. 46, 9\u201314 (2021).","journal-title":"Curr. Opin. Virol."},{"key":"2419_CR45","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.3390\/v14122641","volume":"14","author":"L Amurri","year":"2022","unstructured":"Amurri, L., Reynard, O., Gerlier, D., Horvat, B. & Iampietro, M. Measles virus-induced host immunity and mechanisms of viral evasion. Viruses 14, 2641 (2022).","journal-title":"Viruses"},{"key":"2419_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-025-11651-6","volume":"25","author":"K Ikeuchi","year":"2025","unstructured":"Ikeuchi, K. et al. Comparative effectiveness of antiviral treatment on household transmission of SARS-CoV-2: a retrospective cohort study using administrative data. BMC Infect. Dis. 25, 1213 (2025).","journal-title":"BMC Infect. Dis."},{"key":"2419_CR47","doi-asserted-by":"publisher","first-page":"990","DOI":"10.3201\/eid\/1706.101161","volume":"17","author":"RG Pebody","year":"2011","unstructured":"Pebody, R. G. et al. Use of antiviral drugs to reduce household transmission of pandemic (H1N1) 2009, United Kingdom. Emerg. Infect. Dis. 17, 990\u2013999 (2011).","journal-title":"Emerg. Infect. Dis."},{"key":"2419_CR48","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1503\/cmaj.080724","volume":"180","author":"O Steichen","year":"2009","unstructured":"Steichen, O. & Dautheville, S. Koplik spots in early measles. CMAJ 180, 583 (2009).","journal-title":"CMAJ"},{"key":"2419_CR49","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1038\/nbt1363","volume":"25","author":"WA Marasco","year":"2007","unstructured":"Marasco, W. A. & Sui, J. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat. Biotechnol. 25, 1421\u20131434 (2007).","journal-title":"Nat. Biotechnol."},{"key":"2419_CR50","doi-asserted-by":"publisher","first-page":"e0316926","DOI":"10.1371\/journal.pone.0316926","volume":"20","author":"V Rajendram","year":"2025","unstructured":"Rajendram, V., Paddick, M. & More, J. Measles neutralising antibody levels in patients receiving intravenous immunoglobulin treatment - a sub-analysis of a randomized, cross-over bioequivalence trial. PLoS ONE 20, e0316926 (2025).","journal-title":"PLoS ONE"},{"key":"2419_CR51","doi-asserted-by":"publisher","DOI":"10.1126\/science.adm8693","volume":"384","author":"DS Zyla","year":"2024","unstructured":"Zyla, D. S. et al. A neutralizing antibody prevents postfusion transition of measles virus fusion protein. Science 384, eadm8693 (2024).","journal-title":"Science"},{"key":"2419_CR52","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s44259-025-00125-z","volume":"3","author":"DZH Aw","year":"2025","unstructured":"Aw, D. Z. H., Zhang, D. X. & Vignuzzi, M. Strategies and efforts in circumventing the emergence of antiviral resistance against conventional antivirals. npj Antimicrob. Resist. 3, 54 (2025).","journal-title":"npj Antimicrob. Resist."},{"key":"2419_CR53","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.idc.2010.01.001","volume":"24","author":"L Strasfeld","year":"2010","unstructured":"Strasfeld, L. & Chou, S. Antiviral drug resistance: mechanisms and clinical implications. Infect. Dis. Clin. N. Am. 24, 413\u2013437 (2010).","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"2419_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25497-4","volume":"12","author":"K Wittwer","year":"2021","unstructured":"Wittwer, K. et al. Small-molecule polymerase inhibitor protects non-human primates from measles and reduces shedding. Nat. Commun. 12, 5233 (2021).","journal-title":"Nat. Commun."},{"key":"2419_CR55","doi-asserted-by":"publisher","unstructured":"Lieber, C. M. et al. Developmental candidate GHP-88310\/EIDD-3608 with high tolerability and oral efficacy in measles and respiratory paramyxovirus models. Sci. Adv. https:\/\/doi.org\/10.1126\/sciadv.aef1594 (2025).","DOI":"10.1126\/sciadv.aef1594"},{"key":"2419_CR56","unstructured":"Kekatos, M. RFK Jr. claims measles can be treated with vitamin A, linked to poor diet. Here\u2019s what science says. abcNEWS (14 March 2025); https:\/\/abcnews.go.com\/Health\/rfk-jr-claims-measles-treated-vitamin-linked-poor\/story?id=119713193#:-:text=Vitamin%20A%20as%20a%20form,treat%20measles%2C%22%20she%20concluded"}],"container-title":["Nature Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41564-026-02419-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-026-02419-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-026-02419-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:02:41Z","timestamp":1787929361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41564-026-02419-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":56,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["2419"],"URL":"https:\/\/doi.org\/10.1038\/s41564-026-02419-y","relation":{},"ISSN":["2058-5276"],"issn-type":[{"value":"2058-5276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.M.L. and R.K.P. are co-inventors on a patent filing covering composition and method of use of GHP-88310 for antiviral therapy. This study could affect their personal financial status. R.K.P. reports contract testing from Enanta Pharmaceuticals and Gilead Sciences, outside of the described work. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}